Search

Eytan R Barnea

from New York, NY
Age ~75
Get Report
Also known as:
Eytan Robert Barnea, Eytan Dr Barnea, Eytan P Barnea, Uytan Barnos, Barnea R Eytan
Related to:
Charles BarnesJeandavid Barnea, 47Jean-David Barnea, 48Jacqueline H Barnea, 75Tamiua J Harcum, 48Dennis A Spink, 80Kathleen L Barnes, 78Lindsey W Spink, 46Barnea R Eytan, 64Jacqueline Barnea, 56
Connected to:
Joseph Barnea, 94Leanna R Barnea, 44Matan Barnea, 39Oded Barnea, 69Avery A Barnebey, 62David C Barnebey, 57Harold W Barnebee, 90Kathleen A Barnebey, 72Jennifer M Barneclo, 48Nick A Barneclo, 48

Eytan Barnea Phones & Addresses

  • New York, NY
  • 1697 Lark Ln, Cherry Hill, NJ 08003 (856) 429-2699
  • 1897 Lark Ln, Cherry Hill, NJ 08003
  • Philadelphia, PA
  • 1697 Lark Ln, Cherry Hill, NJ 08003

Work

Company: CamCare - OB/GYN Address: 3 Cooper Plz Suite 104, Camden, NJ 08103 Phones: (856) 541-2229

Education

School / High School: Libera Universita 'vita Salute S Raffaele' Milano, Facolta Di Medicina E Chirurgia 1976

Languages

English • French • Hebrew • Hungarian

Awards

Healthgrades Honor Roll

Ranks

Certificate: Fertility & Reproductive Endocrinology, 2000

Emails

j***[email protected]

Specialities

Reproductive Endocrinology & Infertility

Professional Records

Medicine Doctors

Eytan Barnea Photo 1

Dr. Eytan R Barnea, Camden NJ - MD (Doctor of Medicine)

View page
Specialties:
Reproductive Endocrinology & Infertility
Address:
CamCare - OB/GYN
3 Cooper Plz Suite 104, Camden, NJ 08103
(856) 541-2229 (Phone)
Certifications:
Fertility & Reproductive Endocrinology, 2000
Obstetrics & Gynecology, 2011
Awards:
Healthgrades Honor Roll
Languages:
English
French
Hebrew
Hungarian
Hospitals:
CamCare - OB/GYN
3 Cooper Plz Suite 104, Camden, NJ 08103

Cooper University Hospital
1 Cooper Plaza, Camden, NJ 08103

Lourdes Medical Center of Burlington County
218A Sunset Road, Willingboro, NJ 08046

Our Lady of Lourdes Medical Center
1600 Haddon Avenue, Camden, NJ 08103
Education:
Medical School
Libera Universita 'vita Salute S Raffaele' Milano, Facolta Di Medicina E Chirurgia
Graduated: 1976
Medical School
Presbyterian-Univ. Of Pa
Graduated: 1976
Medical School
McGill University
Graduated: 1976
Medical School
Yale New Haven Hospital
Graduated: 1976
Eytan Barnea Photo 2

Eytan R. Barnea

View page
Specialties:
Obstetrics & Gynecology, Reproductive Endocrinology
Work:
Camcare Health Corporation PediatricsCamcare Health Corporation Obstetrics & Gynecology
817 Federal St STE 300, Camden, NJ 08103
(856) 541-2229 (phone), (856) 541-3340 (fax)
Education:
Medical School
Univ Di Milano, Fac Di Med E Chirurgia, Milano, Italy
Graduated: 1976
Procedures:
Hysterectomy
Electrocardiogram (EKG or ECG)
Myomectomy
Oophorectomy
Ovarian Surgery
Tubal Surgery
Vaccine Administration
Vaginal Delivery
Conditions:
Abnormal Vaginal Bleeding
Complicating Pregnancy or Childbirth
Conditions of Pregnancy and Delivery
Diabetes Mellitus Complicating Pregnancy or Birth
Pelvic Inflammatory Disease (PID)
Languages:
English
Spanish
Description:
Dr. Barnea graduated from the Univ Di Milano, Fac Di Med E Chirurgia, Milano, Italy in 1976. He works in Camden, NJ and specializes in Obstetrics & Gynecology and Reproductive Endocrinology. Dr. Barnea is affiliated with Cooper University Hospital.
Eytan Barnea Photo 3

Eytan Robert Barnea

View page
Specialties:
Obstetrics & Gynecology
Obstetrics
Gynecology
Reproductive Endocrinology
Education:
Universita Degli Studi Di Milano (1976)
Eytan Barnea Photo 4

Eytan R Barnea, Camden NJ

View page
Specialties:
OB-GYN
Address:
817 Federal St, Camden, NJ 08103
Education:
University of Milan, Faculty of Medicine and Surgery - Doctor of Medicine
Yale New Haven Psychiatric Hospital - Fellowship - Reproductive Endocrinology
Yale New Haven Psychiatric Hospital - Fellowship - Endocrinology
Yale New Haven Psychiatric Hospital - Residency - Obstetrics and Gynecology
McGill University Health Centre-The Royal Victoria Hospital - Residency - Obstetrics and Gynecology
Hospital of the University of Pennsylvania - Internship - Flex
Board certifications:
American Board of Obstetrics and Gynecology Certification in Obstetrics & Gynecology
American Board of Obstetrics and Gynecology Sub-certificate in Reproductive Endocrinology/Infertility (Obstetrics & Gynecology)

License Records

Eytan R Barnea

Address:
1697 Lark Ln, Cherry Hill, NJ
Phone:
(856) 429-2699
License #:
130438 - Active
Category:
Health Care
Issued Date:
Nov 17, 2016
Effective Date:
Nov 17, 2016
Expiration Date:
Jan 31, 2019
Type:
Medical Doctor

Business Records

Name / Title
Company / Classification
Phones & Addresses
Eytan Robert Barnea
Eytan Barnea MD
Obgyn
3 Cooper Plz, Camden, NJ 08103
(609) 541-2229

Publications

Isbn (Books And Publications)

Embryonic Medicine and Therapy

View page
Author

Eytan R. Barnea

ISBN #

0192627295

The First Twelve Weeks of Gestation

View page
Author

Eytan R. Barnea

ISBN #

0387535306

Us Patents

Assays For Preimplantation Factor And Preimplantation Factor Peptides

View page
US Patent:
7273708, Sep 25, 2007
Filed:
Jun 28, 2002
Appl. No.:
10/482244
Inventors:
Eytan R. Barnea - Cherry Hill NJ, US
Reuben Renee Gonzales Perez - Watertown MA, US
Paul C. Leavis - Epping NH, US
Assignee:
BioIncept, LLC - Cherry Hill NJ
International Classification:
G01N 33/53
US Classification:
435 71, 435 72, 435 792, 435 794
Abstract:
The present invention relates to assay methods used for detecting the presence of PIF, and to PIF peptides identified using this assay. In particular, the present invention relates to flow cytomery assays for detecting PIF. It is based, at least in part, on the observation that flow cytometry using fluorescently labeled antilymphocyte and anti-platelet antibodies demonstrated an increase in rosette formation in the presence of PIF. It is further based on the observation that flow cytometry demonstrated that monoclonal antibody binding to CD2 decreased in the presence of PIF. The present invention further relates to PIF peptides which, when added to Jurkat cell cultures, have been observed to either (I) decrease binding of anti-CD2 antibody to Jurkat cells; (ii) increase expression of CD2 in Jurkat cells; or (iii) decrease Jurkat cell viability. In additional embodiments, the present invention provides for ELISA assays which detect PIF by determining the effect of a test sample on the binding of anti-CD2 antibody to a CD2 substrate.

Antiproliferative And Antiviral Proteins And Peptides

View page
US Patent:
7476649, Jan 13, 2009
Filed:
Sep 25, 2003
Appl. No.:
10/670490
Inventors:
Eytan R. Barnea - Cherry Hill NJ, US
Paul C. Leavis - Eppins NH, US
Assignee:
Biospectrum, Inc. - Cherry Hill NJ
International Classification:
A61K 38/00
A61K 38/08
C07K 7/06
C07K 14/00
US Classification:
514 2, 514 16, 514 21, 530300, 530329
Abstract:
The present invention relates to peptides and proteins which may be used to inhibit infection or cell proliferation. It is based, at least in part, on the discovery of peptides and proteins isolated from embryonic tissue which have been found to exhibit an antiproliferative effect on a variety of cancer cells and/or to act as broad-spectrum antiviral agents.

Antiproliferative Peptides And Antibodies For Their Detection

View page
US Patent:
7495071, Feb 24, 2009
Filed:
Jul 14, 2005
Appl. No.:
11/181331
Inventors:
Eytan R. Barnea - Cherry Hill NJ, US
Assignee:
BioSpectrum, Inc. - Cherry Hill NJ
International Classification:
C07K 16/00
A61K 38/00
US Classification:
530327, 530328, 530329
Abstract:
The present invention relates to developmental peptides and peptidomimetics thereof, which may be used therapeutically to inhibit abnormal cell proliferation of damaged cells, including cancer cells or virally infected cells. In one embodiment, a seven to eleven amino acid developmental peptide and methods of using the same is provided.

Assays For Preimplantation Factor And Preimplantation Factor Peptides

View page
US Patent:
7670850, Mar 2, 2010
Filed:
Sep 14, 2007
Appl. No.:
11/855495
Inventors:
Eytan R. Barnea - Cherry Hill NJ, US
Ruben Rene Gonzales Perez - Watertown MA, US
Paul C. Leavis - Epping NH, US
Assignee:
BioIncept, LLC - Cherry Hill NJ
International Classification:
G01N 33/53
US Classification:
436510, 435 71
Abstract:
The present invention relates to assay methods used for detecting the presence of PIF, and to PIF peptides identified using this assay. In particular, the present invention relates to flow cytometry assays for detecting PIF. It is based, at least in part, on the observation that flow cytometry using fluorescently labeled anti-lymphocyte and anti-platelet antibodies demonstrated an increase in rosette formation in the presence of PIF. It is further based on the observation that flow cytometry demonstrated that monoclonal antibody binding to CD2 decreased in the presence of PIF. The present invention further relates to PIF peptides which, when added to Jurkat cell cultures, have been observed to either (i) decrease binding of anti-CD2 antibody to Jurkat cells; (ii) increase expression of CD2 in Jurkat cells; or (iii) decrease Jurkat cell viability. In additional embodiments, the present invention provides for ELISA assays which detect PIF by determining the effect of a test sample on the binding of anti-CD2 antibody to a CD2 substrate.

Assays For Preimplantation Factor And Preimplantation Factor Peptides

View page
US Patent:
7670851, Mar 2, 2010
Filed:
Sep 14, 2007
Appl. No.:
11/855539
Inventors:
Eytan R. Barnea - Cherry Hill NJ, US
Ruben Rene Gonzales Perez - Watertown MA, US
Paul C. Leavis - Epping NH, US
Assignee:
BioIncept, LLC - Cherry Hill NJ
International Classification:
G01N 33/53
US Classification:
436510, 435 71
Abstract:
The present invention relates to assay methods used for detecting the presence of PIF, and to PIF peptides identified using this assay. In particular, the present invention relates to flow cytometry assays for detecting PIF. It is based, at least in part, on the observation that flow cytometry using fluorescently labeled anti-lymphocyte and anti-platelet antibodies demonstrated an increase in rosette formation in the presence of PIF. It is further based on the observation that flow cytometry demonstrated that monoclonal antibody binding to CD2 decreased in the presence of PIF. The present invention further relates to PIF peptides which, when added to Jurkat cell cultures, have been observed to either (i) decrease binding of anti-CD2 antibody to Jurkat cells; (ii) increase expression of CD2 in Jurkat cells; or (iii) decrease Jurkat cell viability. In additional embodiments, the present invention provides for ELISA assays which detect PIF by determining the effect of a test sample on the binding of anti-CD2 antibody to a CD2 substrate.

Assays For Preimplantation Factor And Preimplantation Factor Peptides

View page
US Patent:
7670852, Mar 2, 2010
Filed:
Sep 14, 2007
Appl. No.:
11/855586
Inventors:
Eytan R. Barnea - Cherry Hill NJ, US
Ruben Rene Gonzales Perez - Watertown MA, US
Paul C. Leavis - Epping NH, US
Assignee:
BioIncept, LLC - Cherry Hill NJ
International Classification:
G01N 33/53
US Classification:
436510, 435 71
Abstract:
The present invention relates to assay methods used for detecting the presence of PIF, and to PIF peptides identified using this assay. In particular, the present invention relates to flow cytometry assays for detecting PIF. It is based, at least in part, on the observation that flow cytometry using fluorescently labeled anti-lymphocyte and anti-platelet antibodies demonstrated an increase in rosette formation in the presence of PIF. It is further based on the observation that flow cytometry demonstrated that monoclonal antibody binding to CD2 decreased in the presence of PIF. The present invention further relates to PIF peptides which, when added to Jurkat cell cultures, have been observed to either (i) decrease binding of anti-CD2 antibody to Jurkat cells; (ii) increase expression of CD2 in Jurkat cells; or (iii) decrease Jurkat cell viability. In additional embodiments, the present invention provides for ELISA assays which detect PIF by determining the effect of a test sample on the binding of anti-CD2 antibody to a CD2 substrate.

Assays For Preimplantation Factor And Preimplantation Factor Peptides

View page
US Patent:
7678582, Mar 16, 2010
Filed:
Sep 14, 2007
Appl. No.:
11/855519
Inventors:
Eytan R. Barnea - Cherry Hill NJ, US
Ruben Rene Gonzalez Perez - Watertown MA, US
Paul C. Leavis - Epping NH, US
Assignee:
BioIncept, LLC - Cherry Hill NJ
International Classification:
G01N 33/53
US Classification:
436510, 435 71
Abstract:
The present invention relates to assay methods used for detecting the presence of PIF, and to PIF peptides identified using this assay. In particular, the present invention relates to flow cytometry assays for detecting PIF. It is based, at least in part, on the observation that flow cytometry using fluorescently labeled anti-lymphocyte and anti-platelet antibodies demonstrated an increase in rosette formation in the presence of PIF. It is further based on the observation that flow cytometry demonstrated that monoclonal antibody binding to CD2 decreased in the presence of PIF. The present invention further relates to PIF peptides which, when added to Jurkat cell cultures, have been observed to either (i) decrease binding of anti-CD2 antibody to Jurkat cells; (ii) increase expression of CD2 in Jurkat cells; or (iii) decrease Jurkat cell viability. In additional embodiments, the present invention provides for ELISA assays which detect PIF by determining the effect of a test sample on the binding of anti-CD2 antibody to a CD2 substrate.

Assays For Preimplantation Factor And Preimplantation Factor Peptides

View page
US Patent:
7695977, Apr 13, 2010
Filed:
Sep 14, 2007
Appl. No.:
11/855616
Inventors:
Eytan R. Barnea - Cherry Hill NJ, US
Ruben Rene Gonzales Perez - Watertown MA, US
Paul C. Leavis - Epping NH, US
Assignee:
BioIncept, LLC - Cherry Hill NJ
International Classification:
G01N 33/53
US Classification:
436510, 435 71
Abstract:
The present invention relates to assay methods used for detecting the presence of PIF, and to PIF peptides identified using this assay. In particular, the present invention relates to flow cytometry assays for detecting PIF. It is based, at least in part, on the observation that flow cytometry using fluorescently labeled anti-lymphocyte and anti-platelet antibodies demonstrated an increase in rosette formation in the presence of PIF. It is further based on the observation that flow cytometry demonstrated that monoclonal antibody binding to CD2 decreased in the presence of PIF. The present invention further relates to PIF peptides which, when added to Jurkat cell cultures, have been observed to either (i) decrease binding of anti-CD2 antibody to Jurkat cells; (ii) increase expression of CD2 in Jurkat cells; or (iii) decrease Jurkat cell viability. In additional embodiments, the present invention provides for ELISA assays which detect PIF by determining the effect of a test sample on the binding of anti-CD2 antibody to a CD2 substrate.
Control profile
Eytan R Barnea from New York, NY, age ~75 Get Report